Fate Therapeutics Inc SEC filings FATE
Fate Therapeutics Inc has 855 filings in SEC EDGAR's recent list, going back to May 2, 2008. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 12, 2026 |
| DEFA14A | Additional proxy material | Apr 17, 2025 | — |
| DEF 14A | Proxy statement | Apr 17, 2025 | May 29, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2025 | May 29, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2024 | Jun 7, 2024 |
| DEFA14A | Additional proxy material | Apr 21, 2023 | — |
| DEF 14A | Proxy statement | Apr 21, 2023 | — |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 9, 2022 |
| DEFA14A | Additional proxy material | Apr 21, 2021 | — |
| DEF 14A | Proxy statement | Apr 21, 2021 | Jun 2, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2021 | Jun 2, 2021 |
| DEFA14A | Additional proxy material | Mar 20, 2020 | — |
| DEF 14A | Proxy statement | Mar 20, 2020 | May 1, 2020 |
| DEFA14A | Additional proxy material | Apr 8, 2019 | — |
| DEF 14A | Proxy statement | Mar 22, 2019 | May 3, 2019 |
| DEFA14A | Additional proxy material | Mar 16, 2018 | — |
| DEF 14A | Proxy statement | Mar 16, 2018 | May 2, 2018 |
| DEFA14A | Additional proxy material | Mar 22, 2017 | — |
| DEF 14A | Proxy statement | Mar 22, 2017 | May 2, 2017 |
| PRE 14A | Preliminary proxy statement | Feb 28, 2017 | May 2, 2017 |
| DEFA14A | Additional proxy material | Mar 30, 2016 | — |
| DEF 14A | Proxy statement | Mar 30, 2016 | May 11, 2016 |
| DEFA14A | Additional proxy material | Apr 2, 2015 | — |
| DEF 14A | Proxy statement | Apr 2, 2015 | May 13, 2015 |
| DEF 14A | Proxy statement | Apr 25, 2014 | Jun 6, 2014 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FATE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434316
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.